[关键词]
[摘要]
目的 研究苦碟子注射液联合依达拉奉注射液治疗急性脑梗死的临床疗效。方法 选择2014年1月—2017年12月杨凌示范区医院的急性脑梗死患者71例作为研究对象,按治疗方法将患者分为对照组35例和观察组36例。对照组静脉滴注依达拉奉注射液,30 mg/次,2次/d;观察组在对照组的基础上静脉滴注苦碟子注射液,40 mL/次,1次/d。两组均持续治疗2周。观察两组患者的临床治疗效果,比较两组患者治疗前后日常生活活动能力(ADL)量表评分、美国国立卫生研究院卒中量表(NIHSS)评分、血清白介素-6、肿瘤坏死因子-α、白介素-23水平的变化。结果 治疗后,观察组的治疗有效率为91.67%,明显高于对照组的71.43%,差异具有统计学意义(P<0.05)。两组治疗后的ADL量表评分均明显升高,NIHSS量表评分明显降低(P<0.05),且观察组ADL量表和NIHSS量表评分均显著优于对照组(P<0.05)。两组治疗后的白介素-6、肿瘤坏死因子-α和白介素-23水平均明显降低(P<0.05),且观察组血清炎症因子水平明显低于对照组(P<0.05)。结论 苦碟子注射液联合依达拉奉注射液对急性脑梗死患者具有较为满意的治疗效果,可以显著降低血清炎症因子,提高患者的日常生活能力,促进神经功能的恢复,且不会增加不良反应。
[Key word]
[Abstract]
Objective To investigate the clinical effect of Kudiezi Injection combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (71 cases) with cute cerebral infarction in Yangling Demonstration Zone Hospital from January 2014 to December 2017 were divided into control group (35 cases) and observation group (36 cases) by treatment methods. Patients in the control group were iv administered with Edaravone Injection, 30 mg/time, twice daily. Patients in the observation group were iv administered with Kudiezi Injection on the basis of control group, 40 mL/time, once daily. Patients in two groups were treated for 2 weeks. The clinical effects in two groups were observed, and the levels of ADL scale, NIHSS scale, serum IL-6, TNF-α, and IL-23 before and after treatment between two groups were compared. Results After treatment, the effective rate in the observation group was 91.67%, which was significantly higher than 71.43% in the control group (P<0.05). After treatment, the scores of ADL scale in two groups was increased significantly, but the score of NIHSS scale was significantly decreased (P<0.05), and the ADL scale and NIHSS scale in the observation group was better than those in the control group (P<0.05). After treatment, the levels of IL-6, TNF-α, and IL-23 in two groups were significantly decreased (P<0.05), and the serum inflammatory factors in the observation group was significantly lower than those in the control group (P<0.05). Conclusions Kudiezi Injection combined with Edaravone Injection has a satisfactory therapeutic effect on patients with acute cerebral infarction, which can significantly reduce serum inflammatory factors, improve daily living ability, promote recovery of neurological function, and would not increase adverse reactions.
[中图分类号]
R971
[基金项目]